Yuanyuan He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuanyuan He has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Gratien Twagirayezu
State Key Laboratory of Environmental Geochemistry, Institute of Geochemistry, Chinese Academy of Sciences, Guiyang, China
1 shared publication - Hong Zhang
Department of Emergency Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China
1 shared publication - Huarui Bao
Department of Emergency Internal Medicine
1 shared publication Jialin Huang
First Affiliated Hospital of Anhui Medical University
1 shared publicationJiarun Mo
School of life Sciences, Lanzhou University, Lanzhou 730070, China
1 shared publication- Lin Yang
National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China
1 shared publication
Latest Publications
- 16 July 2022
- Published by Elsevier in Science of The Total Environment
- Vol. 846, 157394
Transcriptome analysis reveals manganese tolerance mechanisms in a novel native bacterium of Bacillus altitudinis strain HM-12
- 16 July 2022
- Published by Elsevier in Science of The Total Environment
- Vol. 846, 157394
Transcriptome analysis reveals manganese tolerance mechanisms in a novel native bacterium of Bacillus altitudinis strain HM-12
- Open Access
- 29 March 2021
- Published by Springer Nature in Research Square
What can the neurological manifestations of COVID-19 tell us : a meta-analysis
Background Covid-19 became a global pandemic in 2019. Studies have shown that coronavirus can cause neurological symptoms, but clinical studies on its neurological symptoms are limited. In this meta-analysis, we aim to gather and discuss COVID-19 various neurological symptoms of infection, and to assess the prevalence of each of the nervous system symptoms, and characterized by neurological in-depth discussions of nervous system damage mechanism, biomarkers and inspection methods, recovery and prognosis, and provide the research behind the potential target and direction. Methods We systematically searched all published English literature related to the neurological manifestations of COVID-19 from January 1, 2020 to November 20, 2020 in Pubmed, Embase, and Cochrane library.The keywords used were COVID-19 and terminology related to nervous system performance.All included studies were selected by two independent reviewers using EndNote and NoteExpress software, any disagreement was resolved by consensus or by a third reviewer, and the selected data was then collected for meta-analysis using a random-effects model. Results A total of 62 articles (n =32729) were included in the study, and the meta-analysis showed that the most common neurological manifestations of COVID-19 were altered mental status (39% ; 95% CI 0.17-0.64 ; I 2 98.59%), encephalopathy (37% ; 95% CI 0.17-0.60 ; I 2 97.36%), myalgia(31% ; 95% CI 0.25-0.38; I 2 98.79%), headache(30% ; 95% CI 0.22-0.37; I 2 99.28%), smell impairment(28% ; 95% CI 99.57% ; I 2 0.17-0.39), taste dysfunction (27% ; 95% CI 0.18 -0.38 ; I 2 99.35%), acute ischemic stroke (23% ; 95% CI 0.06-0.47 ; I 2 99.30%), alteration of consciousness(17% ; 95% CI 0.06-0.31 ; I 2 96.78%), dizziness (10% ; 95% CI 0.06-0.15; I 2 95.30%), intracerebral haemorrhage (7% ; 95% CI 0.02-0.14 ; I 2 93.64%), vision impairment(5% ; 95% CI 0.02-0.10 ; I 2 92.73%), seizure(2% ; 95% CI 0.01-0.04 ; I 2 84.67%). Conclusions Neurological symptoms are common and varied in Covid-19 infections, and a growing number of reports suggest that the prevalence of neurological symptoms may be increasing. In the future, the role of COVID-19 neurological symptoms in the progression of COVID-19 should be further studied, and its pathogenesis and assessment methods should be explored, so as to detect and treat early neurological complications of COVID-19 and reduce mortality.
- 29 March 2021
- Published by Springer Nature in Research Square
Open AccessWhat can the neurological manifestations of COVID-19 tell us : a meta-analysis
Background Covid-19 became a global pandemic in 2019. Studies have shown that coronavirus can cause neurological symptoms, but clinical studies on its neurological symptoms are limited. In this meta-analysis, we aim to gather and discuss COVID-19 various neurological symptoms of infection, and to assess the prevalence of each of the nervous system symptoms, and characterized by neurological in-depth discussions of nervous system damage mechanism, biomarkers and inspection methods, recovery and prognosis, and provide the research behind the potential target and direction. Methods We systematically searched all published English literature related to the neurological manifestations of COVID-19 from January 1, 2020 to November 20, 2020 in Pubmed, Embase, and Cochrane library.The keywords used were COVID-19 and terminology related to nervous system performance.All included studies were selected by two independent reviewers using EndNote and NoteExpress software, any disagreement was resolved by consensus or by a third reviewer, and the selected data was then collected for meta-analysis using a random-effects model. Results A total of 62 articles (n =32729) were included in the study, and the meta-analysis showed that the most common neurological manifestations of COVID-19 were altered mental status (39% ; 95% CI 0.17-0.64 ; I 2 98.59%), encephalopathy (37% ; 95% CI 0.17-0.60 ; I 2 97.36%), myalgia(31% ; 95% CI 0.25-0.38; I 2 98.79%), headache(30% ; 95% CI 0.22-0.37; I 2 99.28%), smell impairment(28% ; 95% CI 99.57% ; I 2 0.17-0.39), taste dysfunction (27% ; 95% CI 0.18 -0.38 ; I 2 99.35%), acute ischemic stroke (23% ; 95% CI 0.06-0.47 ; I 2 99.30%), alteration of consciousness(17% ; 95% CI 0.06-0.31 ; I 2 96.78%), dizziness (10% ; 95% CI 0.06-0.15; I 2 95.30%), intracerebral haemorrhage (7% ; 95% CI 0.02-0.14 ; I 2 93.64%), vision impairment(5% ; 95% CI 0.02-0.10 ; I 2 92.73%), seizure(2% ; 95% CI 0.01-0.04 ; I 2 84.67%). Conclusions Neurological symptoms are common and varied in Covid-19 infections, and a growing number of reports suggest that the prevalence of neurological symptoms may be increasing. In the future, the role of COVID-19 neurological symptoms in the progression of COVID-19 should be further studied, and its pathogenesis and assessment methods should be explored, so as to detect and treat early neurological complications of COVID-19 and reduce mortality.
- Open Access
- 27 April 2020
- Published by Wiley in Disease Markers
- Vol. 2020, 1-9
Diagnostic Value of Neutrophil-Lymphocyte Ratio for Predicting the Severity of Acute Pancreatitis: A Meta-Analysis
Background. Acute pancreatitis (AP) is a life-threatening disease caused by a variety of factors, and once it progresses to severe acute pancreatitis, the prognosis is poor. The purpose of this study was to investigate the diagnostic value of the neutrophil-lymphocyte ratio (NLR) for predicting the severity of acute pancreatitis. Materials and Methods. We searched the databases of PubMed, EMBASE, Web of Science, and Cochrane Library to identify eligible studies using the NLR to predict the severity of AP. The sensitivity (SEN), specificity (SPE), negative likelihood ratio (NLR), positive likelihood ratio (PLR), diagnostic odds ratio (DOR), and area under the receiver operating characteristic curve (AUC) were combined using a bivariate mixed model. Results. A total of 10 articles containing 394 cases and 1319 controls were included in the study. The combined SEN, SPE, NLR, PLR, DOR, and AUC are 79% (73%-84%), 71% (59%-80%), 0.30 (0.21-0.41), 2.7 (1.8-4.0), 9 (5-18), and 0.82 (0.78-0.85), respectively. Conclusions. NLR has a moderately high diagnostic value in predicting the severity of acute pancreatitis.
- 27 April 2020
- Published by Wiley in Disease Markers
- Vol. 2020, 1-9
Open AccessDiagnostic Value of Neutrophil-Lymphocyte Ratio for Predicting the Severity of Acute Pancreatitis: A Meta-Analysis
Background. Acute pancreatitis (AP) is a life-threatening disease caused by a variety of factors, and once it progresses to severe acute pancreatitis, the prognosis is poor. The purpose of this study was to investigate the diagnostic value of the neutrophil-lymphocyte ratio (NLR) for predicting the severity of acute pancreatitis. Materials and Methods. We searched the databases of PubMed, EMBASE, Web of Science, and Cochrane Library to identify eligible studies using the NLR to predict the severity of AP. The sensitivity (SEN), specificity (SPE), negative likelihood ratio (NLR), positive likelihood ratio (PLR), diagnostic odds ratio (DOR), and area under the receiver operating characteristic curve (AUC) were combined using a bivariate mixed model. Results. A total of 10 articles containing 394 cases and 1319 controls were included in the study. The combined SEN, SPE, NLR, PLR, DOR, and AUC are 79% (73%-84%), 71% (59%-80%), 0.30 (0.21-0.41), 2.7 (1.8-4.0), 9 (5-18), and 0.82 (0.78-0.85), respectively. Conclusions. NLR has a moderately high diagnostic value in predicting the severity of acute pancreatitis.
- 1 October 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36, e32-E32
A3937 Genetic Polymorphisms of SP-B and Risk of Obstructive Sleep Apnea
To investigate whether polymorphisms of the surfactant protein B (SP-B) gene are associated with or increase the susceptibility to the development of obstructive sleep apnea (OSA). A total of 345 subjects (169 severe OSA patients, 176 controls) who underwent polysomnography (PSG) were continuously recruited from the Hypertension Center of the People's Hospital of Xinjiang from April to December 2016. Three candidate single nucleotide polymorphisms (SNPs) of the SP-B gene (rs1130866, rs2077079 and rs3024791) were selected and the genotype identification were determined by Kompetitive Allele Specifc PCR genotyping system. The frequencies of rs1130866 genotypes CC, CT and TT were 60.87%, 32.3% and 6.83% in severe OSA group, and 42.35%, 49.41% and 8.24% in the non-OSA group respectively. The genotype distributions of 3 polymorphisms in additive, allele and recessive model showed statistically significant difference between severe OSA and non-OSA group (P < 0.05). After adjustment of age, gender, BMI, smoking and alcohol history, multivariate linear regression showed that genotype CC of rs1130866 contributed as risk factor to OSA (OR = 2.885, 95%CI: 1.657–5.023, P < 0. 001). However, the frequencies of polymorphism of rs2077079 and rs3024791 showed no significant difference between the two groups (P > 0.05). The polymorphism (rs1130866) in SP-B gene potentially involved in the process of the loss of a potential N-linked, amino-terminus glycosylation site of pro-SP-B and may be related to OSA by the surfactant dysfunction in severe OSA subjects.
- 1 October 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36, e32-E32
A3937 Genetic Polymorphisms of SP-B and Risk of Obstructive Sleep Apnea
To investigate whether polymorphisms of the surfactant protein B (SP-B) gene are associated with or increase the susceptibility to the development of obstructive sleep apnea (OSA). A total of 345 subjects (169 severe OSA patients, 176 controls) who underwent polysomnography (PSG) were continuously recruited from the Hypertension Center of the People's Hospital of Xinjiang from April to December 2016. Three candidate single nucleotide polymorphisms (SNPs) of the SP-B gene (rs1130866, rs2077079 and rs3024791) were selected and the genotype identification were determined by Kompetitive Allele Specifc PCR genotyping system. The frequencies of rs1130866 genotypes CC, CT and TT were 60.87%, 32.3% and 6.83% in severe OSA group, and 42.35%, 49.41% and 8.24% in the non-OSA group respectively. The genotype distributions of 3 polymorphisms in additive, allele and recessive model showed statistically significant difference between severe OSA and non-OSA group (P < 0.05). After adjustment of age, gender, BMI, smoking and alcohol history, multivariate linear regression showed that genotype CC of rs1130866 contributed as risk factor to OSA (OR = 2.885, 95%CI: 1.657–5.023, P < 0. 001). However, the frequencies of polymorphism of rs2077079 and rs3024791 showed no significant difference between the two groups (P > 0.05). The polymorphism (rs1130866) in SP-B gene potentially involved in the process of the loss of a potential N-linked, amino-terminus glycosylation site of pro-SP-B and may be related to OSA by the surfactant dysfunction in severe OSA subjects.
- Open Access
- 23 March 2018
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 62 (2) , 212-220
Short-term insulin intensive therapy decreases MCP-1 and NF-κB expression of peripheral blood monocyte and the serum MCP-1 concentration in newlydiagnosed type 2 diabetics
Keywords Type 2 diabetes; insulin intensive therapy; MCP-1; NF-κB
- 23 March 2018
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 62 (2) , 212-220
Open AccessShort-term insulin intensive therapy decreases MCP-1 and NF-κB expression of peripheral blood monocyte and the serum MCP-1 concentration in newlydiagnosed type 2 diabetics
Keywords Type 2 diabetes; insulin intensive therapy; MCP-1; NF-κB